Introduction
============

Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death in women and the leading cause of death from gynaecological malignancies \[[@B1]\]. Survival rates have changed little since the early 1980's despite the use of new chemotherapeutical drugs, with only 40% of all stages and 15-30% of patients with widespread metastatic disease surviving 5 years after the initial treatment \[[@B2]\]. This poor overall prognosis is the result of a combination of factors including a lack of distinctive symptoms and sensitive/specific tumour markers at an early stage, drug resistance for advanced disease, and a limited understanding of the early-initiating events and early stages of EOC development.

The dualistic paradigm
----------------------

Among the different tumours arising from the ovary 90% are of epithelial origin \[[@B3]\]. The major histotypes (serous, endometrioid, mucinous, and clear cell) are partly genetically distinguishable as shown by various high-throughput studies in the past fifteen years \[[@B4]\]. Recent findings suggest that epithelial tumours of the ovary may be grouped on the basis of their genetic alterations into a dualistic model that subdivides the various histological types of EOC into two broad categories. The slowly developing tumours (Type I) include low grade serous, endometrioid, mucinous, and a subset of clear cell carcinomas \[[@B5]-[@B7]\] and are characterised by genetic alterations in *KRAS*, *BRAF*, *CTNNB1*, *PTEN*, *ARID1A*, *FBXW74*, *PIK3CA*, *PPP2R1A*, and *TGFBR2*\[[@B7]-[@B12]\]. The more aggressive Type II tumours harbour mutations in *TP53*, *BRCA1*, and *BRCA2*\[[@B8]\]. A more systematic characterization of Type II tumours, in particular high grade serous ovarian cancers, was performed by The Cancer Genome Atlas (TCGA). The Profiling of 489 samples for differential mRNA and miRNA expression, DNA copy number changes, promoter DNA methylation, and whole exome DNA sequencing revealed that almost all samples comprised *TP53* mutations and significantly recurring somatic mutations in *NF1*, *BRCA1*, *BRCA2*, *RB1*, and *CDK12*\[[@B13]\].

Ovarian surface epithelium and tubal epithelium as possible tumour origins
--------------------------------------------------------------------------

The monolayer of epithelial cells covering the outer surface of the ovary (OSE) has traditionally been thought to be the site of origin of epithelial ovarian cancer \[[@B1]\]. This is supported by a recent study focusing on a stem cell niche located at the hilum region and a transitional area between OSE, mesothelium and tubal epithelium. In a comprehensive experimental mouse model the authors demonstrate that stem cell-like OSE cells have the potential to develop into EOC \[[@B14]\]. Another theory proposes the normal epithelium of the fallopian tube (serous), endometrium (endometrioid) and endocervix (mucinous) as the origin of the respective EOC histotypes \[[@B15],[@B16]\]. According to the concept of extra-uterine Müllerian epithelium, the fallopian tube fimbria is proposed to be the primary origin of the high grade serous ovarian carcinoma, the most common EOC subtype and frequently harbouring *TP53* and *IL-6* mutations \[[@B17],[@B18]\]. This is supported by the presence of early neoplastic serous tubal intraepithelial lesions (STIL) in prophylactically removed fallopian tubes of BRCA mutations-carrying women \[[@B19]-[@B21]\]. Those tubal fimbria displayed characteristic features such as *TP53* mutations, DNA damage, and secretory cells, suggesting the tubal fimbria as the precursor for high grade serous ovarian cancers \[[@B20],[@B22],[@B23]\]. This was further supported by more recent studies identifying the tubal secretory cells as potential neoplastic precursors at the tubal fimbria. These cells carry *TP53* mutations, show elevated γH2AX expression, a marker of DNA damage, and express Ki-67 and PAX2, two proliferation markers also expressed in serous tubal intraepithelial carcinomas and high grade serous ovarian carcinomas \[[@B24]-[@B27]\]. In contrast, epithelial-specific marker such as Calretinin and PAX8 do not seem suitable in the proof of EOC origin \[[@B28]\]. Recently, it has been demonstrated in a *Brca*, *Tp53*, *Pten* genetic mouse model that *de novo* high grade serous ovarian carcinoma are originated from the fallopian tube secretory epithelium and that these tumours are correlated with high grade serous carcinoma tumour markers and genomic alterations of the human TCGA data set \[[@B29]\].

Serous carcinomas of the ovary, tube and peritoneum
---------------------------------------------------

Serous ovarian- (SOC), tubal- (STC), and peritoneal- (SPC) cancers are remarkably similar in term of morphology \[[@B30],[@B31]\], genetics \[[@B32]\], and clinical behaviour and epidemiology \[[@B33]\]. SPC and SOC patients also have a comparable survival rate that, however, is markedly distinct from that of patients with low grade SOC metastasizing to distant locations. Cell lines have long been considered important and useful *in vitro* models to investigate the molecular nature and the pathological processes underlying the development of ovarian, tubal, and peritoneal tumours, and their progression to advanced diseases, and even to search for diagnostic or prognostic tumour markers as well as for therapeutic targets.

Ovarian cancer cell lines need better characterization
------------------------------------------------------

Falling short of the use of *in vivo* animal models, cancer cell lines as *in vitro* models have proven invaluable experimental tools for many decades in basic research. Cancer cell lines can be grown continuously in culture, allowing countless experiments to be performed without the necessary restrictions required for *in vivo* models. However, due to few regulations for the development and testing of these cell lines, the question arises as to the quality of long-time established ovarian cancer cell lines. Often laboratories obtain cell lines from collaborating groups and trust in their identification of cells. Conducting research on the basis of such cell lines means not only a waste of a great deal of money and time but also a risk to steer research in an undesired direction.

It is therefore of great importance to define and establish a world-wide standard applicable to all cell lines that are commercially available for research, in order to ensure that only high-quality cancer cell lines with an unequivocal molecular identity and source are distributed to the research community.

We performed a web search for currently available banks for cells and cell lines using the terms 'cell bank', 'cell lines', and 'cell line bank'. Only web pages in English and containing normal or cancer ovarian, tubal, and peritoneal cell lines were included in the study. PubMed (<http://www.ncbi.nlm.nih.gov/>) was also searched to retrieve references provided by these cell banks reporting additional details of the stocked cell lines. We also included a recent publication in which the copy-number changes, mutations, and mRNA expression profiles in ovarian cancer cell lines were compared to those of high grade SOC (TCGA, <http://cancergenome.nih.gov/>) \[[@B34]\].

Commercially available ovarian cancer cell lines
------------------------------------------------

Five cell banks worldwide that stock and distribute normal and/or ovarian cancer cell lines were identified. These are the American Type Culture Collection (ATCC), the European Collection of Cell Cultures (ECACC), the German Collection of Microorganisms and Cell Cultures (DSMZ), the Japanese Collection of Research Bioresources (JCRB), and the National Cell Bank of Iran (NCBI) (Table  [1](#T1){ref-type="table"}). Remarkably, the Australian cell bank (Cell Bank Australia) does not stock ovarian cell lines.

###### 

Ovarian cancer cell line banks

  **ID**               **Name**                                                                       **Homepage**
  -------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------
  ATCC                 American Type Culture Collection                                               <http://www.lgcstandards-atcc.org>
  ECACC                European Collection of Cell Cultures, a part of the Health Protection Agency   <http://www.phe-culturecollections.org.uk/collections/ecacc.aspx>
  DSMZ                 German Collection of Microorganisms and Cell Cultures                          <http://www.dsmz.de/>
  JCRB                 Japanese Collection of Research Bioresources                                   <http://cellbank.nibio.go.jp/>
  CellBank Australia   Australian cell bank -- Cell Bank Australia                                    <http://www.cellbankaustralia.com/>
  NCBI                 National Cell Bank of Iran                                                     <http://ncbi.pasteur.ac.ir/>

Our search algorithm retrieved 153 cell lines. ECAAC distributes almost 40% of all publicly available cell lines, followed by JCRB (19%). A number of cell lines (7.2%) are distributed by two or more cell banks. A listing of the ID number, cell line designation (name), origin, and source of the retrieved normal and malignant ovarian, tubal, and peritoneal cell lines is presented in Tables  [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. About two thirds (68.0%) of the normal and ovarian cancer cell lines used in research is of human and about one fourth (23.5%) of Chinese hamster (*Cricetulus griseus*) origin. About 3% originate from mice (*Mus musculus*) and 4.5% from various species such as *Spodoptera frugiperda* (Fall armyworm), *Esox lucius* (Northern pike fish), *Ictalurus punctatus* (Channel catfish), and *Sus domesticus* (Domestic pig). Strikingly, one third of the 104 described human ovarian cancer-derived cell lines were in reality not from ovarian tissue but from peritoneal ascites (21.2%), pleural fluid (3.8%), or metastatic masses (6.7%).

###### 

Human cell lines originated from ovarian cancer or human ovarian surface epithelium

  **ID number**    **Cell line**                        **Origin**                          **Source**
  --------------- --------------- ------------------------------------------------------ -----------------
  1                     222                                                                       
  2                    2008                               Ovary                                   
  3                 2008/C13.R                    Ovarian adenocarcinoma                       NCBI
  4                41M^a^/OAW28                   Ovarian cancer ascites                       ECACC
  5                  41 M cisR                    Ovarian cancer ascites                          
  6                    59 M                       Ovarian cancer ascites                       ECACC
  7                    A2780                      Ovarian adenocarcinoma                       ECACC
  8                  A2780ADR                 Ovarian adenocarcinoma; A2780                    ECACC
  9                  A2780cis                 Ovarian adenocarcinoma; A2780                    ECACC
  10                 A2780 CP                     Ovarian adenocarcinoma                       NCBI
  11                  A2780 S                     Ovarian adenocarcinoma                       NCBI
  12                  Caov-3                      Ovarian adenocarcinoma                       ATCC
  13                  Caov-4        Metastatic fallopian tube mass from ovarian tumour       ATCC/NCBI
  14                    CH1                       Ovarian adenocarcinoma                          
  15                  CH1cisR                     Ovarian adenocarcinoma                          
  16                 COLO-704         Metastatic colonic ascites from ovarian tumour           DSMZ
  17                  COV318                      Ovarian cancer ascites                       ECACC
  18                  COV362                 Ovarian cancer pleural effusion                   ECACC
  19                 COV362.4            Ovarian cancer pleural effusion; COV362               ECACC
  20                  COV413A          Metastatic sigmoid mass from ovarian tumour             ECACC
  21                  COV413B        Metastatic bladder dome mass from ovarian tumour          ECACC
  22                  COV434       Ovarian granulosa tumour from a solid primary tumour        ECACC
  23                  COV504                     Ovarian pleural effusion                      ECACC
  24                  COV644                  Ovarian cancer (primary tumor)                   ECACC
  25                  EFO-21                      Ovarian cancer ascites                       DSMZ
  26                   EFO27           Metastatic omental mass from ovarian tumour             DSMZ
  27                   ES-2                       Ovarian adenocarcinoma                       ATCC
  28                  FU-OV-1                     Malignant ovarian mass                       DSMZ
  29                   HAC-2           Ovarian cancer cell derived from mesonephros            JCRB
  30                  Hey-A8                              Ovary                                CCLE
  31                 HOSE 6-3                   Ovarian surface epithelium                        
  32                 HOSE 17-1                  Ovarian surface epithelium                        
  33                 HOSE 105                   Ovarian surface epithelium                        
  34                 HOSE 111                   Ovarian surface epithelium                        
  35                 HOSE 129                   Ovarian surface epithelium                        
  36                 HOSE 130                   Ovarian surface epithelium                        
  37                  Hs 38.T                        Ovarian teratoma                          ATCC
  38                 Hs 571.T                     Ovarian adenocarcinoma                       ATCC
  39                  Hs904.T                                                                     
  40                  IGROV1                      Ovarian adenocarcinoma                          
  41                  JHOC-5                      Ovarian adenocarcinoma                       CCLE
  42                  JHOM-1                      Ovarian adenocarcinoma                       CCLE
  43                  JHOM-2B                     Ovarian adenocarcinoma                       CCLE
  44                  JHOS-2                      Ovarian adenocarcinoma                       CCLE
  45                  JHOS-4                      Ovarian adenocarcinoma                       CCLE
  46                 KURAMOCHI                    Ovarian cancer ascites                       JCRB
  47                   MCAS                       Ovarian adenocarcinoma                       JCRB
  48               NCC-OvC-K119                   Ovarian adenocarcinoma                       JCRB
  49                OAW28/41 M                    Ovarian cancer ascites                       ECACC
  50                   OAW42                      Ovarian cancer ascites                       ECACC
  51                  OC 314                      Ovarian cancer ascites                       CCLE
  52                  OC 315                      Ovarian adenocarcinoma                       CCLE
  53                  OC 316                      Ovarian cancer ascites                       CCLE
  54               ONCO-DG-1^a^                   Ovarian adenocarcinoma                       DSMZ
  55                   OV-7          Ovarian adenocarcinoma derived from solid tumour          ECACC
  56                   OV17R                      Ovarian cancer ascites                       ECACC
  57                   OV56                       Ovarian cancer ascites                       ECACC
  58                   OV-58                      Ovarian cancer ascites                       ECACC
  59                   OV-90                      Ovarian cancer ascites                       ATCC
  60                OV-1063^a^                                                                    
  61                OVC1-PI 32                            Ovary                                NCBI
  62                  OVCAR-3                     Ovarian cancer ascites                     ATCC/NCBI
  63                  OVCAR-4                     Ovarian adenocarcinoma                       CCLE
  64                  OVCAR-8                     Ovarian adenocarcinoma                       CCLE
  65                   OVISE                Metastatic ovarian adenocarcinoma                JCRB/CCLE
  66                   OVK18                      Ovarian adenocarcinoma                       CCLE
  67                  OVKATE                      Ovarian adenocarcinoma                       JCRB
  68                  OVMANA                      Ovarian adenocarcinoma                       JCRB
  69                 OVMIU^a^                     Ovarian adenocarcinoma                       JCRB
  70                OVMIU-II^a^                   Ovarian adenocarcinoma                       JCRB
  71                  OVSAHO                      Ovarian adenocarcinoma                       JCRB
  72                 OVSAYO^a^                    Ovarian adenocarcinoma                       JCRB
  73                  OVTOKO                      Ovarian adenocarcinoma                       JCRB
  74                   PA-1                       Ovarian cancer ascites                  ATCC/JCRB/ECACC
  75                PA-1/6TG-r                    Ovarian cancer ascites                       JCRB
  76                   PEA1                  Ovarian cancer pleural effusion                   ECACC
  77                   PEA2                       Ovarian cancer ascites                       ECACC
  78                   PEO1                       Ovarian cancer ascites                       ECACC
  79                   PEO4                  Ovarian cancer pleural effusion                   ECACC
  80                   PEO6                       Ovarian cancer ascites                       ECACC
  81                 PEO14^b^                     Ovarian cancer ascites                       ECACC
  82                   PEO16                      Ovarian cancer ascites                       ECACC
  83                 PEO23^b^                     Ovarian cancer ascites                       ECACC
  84                    RKN                       Ovarian adenocarcinoma                       JCRB
  85                 RMG-I^a^                     Ovarian adenocarcinoma                       JCRB
  86                  RMG-II                      Ovarian adenocarcinoma                       JCRB
  87                 RMUG-L^a^                    Ovarian adenocarcinoma                       JCRB
  88                  RMUG-S                      Ovarian adenocarcinoma                       JCRB
  89                  RTSG^c^                     Ovarian adenocarcinoma                       JCRB
  90                   SCC60                                                                      
  91                  SK-OV-3                     Ovarian cancer ascites                  ATCC/NCBI/ECACC
  92                   SNU-8                      Ovarian adenocarcinoma                       CCLE
  93                  SNU-119                     Ovarian adenocarcinoma                       CCLE
  94                  SNU-840                     Ovarian adenocarcinoma                       CCLE
  95                  SW 626            Ovarian metastatic mass from colon tumour           ATCC/ECACC
  96                  TE 84.T                     Ovarian adenocarcinoma                       ATCC
  97                  TO14^b^          Metastatic omental mass from ovarian tumour             ECACC
  98                  TOV-21G                     Malignant ovarian mass                       ATCC
  99                  TOV-81D                     Malignant ovarian mass                          
  100                TOV-112D                     Malignant ovarian mass                       ATCC
  101                 TYK-nu                      Ovarian adenocarcinoma                       JCRB
  102               TYK-nu.CP-r                   Ovarian adenocarcinoma                       JCRB
  103                 UC1-101                     Ovarian adenocarcinoma                          
  104                 UC1-107                                                                     

^a^Possible cross contamination or misidentification (JCRB, DSMZ: Database of Cross-Contaminated or misidentified cell lines, Capes-Davis, A. and Freshney, R.I. Version 6.7, Table  [1](#T1){ref-type="table"} 27.6.2011). Cross contaminated with OVCAR-3 (ONCO-DG-1); ^b^All these cell lines were derived from the same patient.

###### 

Non-human cell line originated from the ovary

  ***Cricetulus griseus*-- Chinese hamster**                                                                
  ---------------------------------------------- -------------------------------- ------------------------- -----------------
  105                                            A2                               Ovary                     ECACC
  106                                            A2H                              Ovary; A2                 ECACC
  107                                            AR-EcoScreen                     Ovary                     JCRB
  108                                            CHO                              Ovary                     ECACC/NCBI
  109                                            CHO 1--15 500                    Ovary                     NCBI
  110                                            CHO CD28                         Ovary                     NCBI
  111                                            CHO-CHRM1                        Ovary; CHO-K1             ECACC
  112                                            CHO-CHRM2                        Ovary; CHO-K1             ECACC
  113                                            CHO-CHRM5                        Ovary; CHO-K1             ECACC
  114                                            CHO DG-44                        Ovary                     NCBI
  115                                            CHO/dhFr-                        Ovary                     ECACC/DSMZ/NCBI
  116                                            CHO/dhFr- Ac-free                Ovary; CHO/dhFr-          ECACC
  117                                            CHO-FFAR2                        Ovary; CHO-K1             ECACC
  118                                            CHO-GPR120                       Ovary; CHO-K1             ECACC
  119                                            CHO/HGPRT                        Ovary                     JCRB
  120                                            CHO (His9)                       Ovary                     JCRB
  121                                            CHO-K1                           Ovary; CHO                ECACC/JCRB/DSMZ
  122                                            CHO-K1/SF                        Ovary; CHO-K1             ECACC
  123                                            CHO-OPRL1                        Ovary; CHO-K1             ECACC
  124                                            CHO (pMAM-HSluc)                 Ovary                     JCRB
  125                                            CHO (pMAM-luc)                   Ovary                     JCRB
  126                                            CHO Protein-Free                 Ovary; CHO                ECACC
  127                                            CHO-SSTR1                        Ovary; CHO-K1             ECACC
  128                                            GRL101 (KC7)                     Ovary                     ECACC
  129                                            GRL101 (MIX)                     Ovary                     ECACC
  130                                            M1WT3                            Ovary; CHO-K1             ECACC
  131                                            NCTC 4206                        Peritoneum; B14FAF28-G3   ECACC
  132                                            P22                              Ovary                     ECACC
  133                                            RR-CHOKI                         Ovary; CHO-K1             ECACC
  134                                            T02J-7/10 (CHO-M3 (CHRM3))       Ovary; CHO-K1             ECACC
  135                                            T02J-9/10 (CHO-H2 (HRH2))        Ovary; CHO-K1             ECACC
  136                                            T02J-10/10 (CHO-GCGR (GCGR))     Ovary; CHO-K1             ECACC
  137                                            T26J-1/09 (CHO-Beta-2 (ADRB2))   Ovary; CHO-K1             ECACC
  138                                            T35J-5/09 (CHO-FFAR3 (FFAR3))    Ovary; CHO-K1             ECACC
  139                                            UT-1                             Ovary; CHO-K1             ECACC
  140                                            XrS6                             Ovary; CHO-K1             ECACC
  141                                            Xrs6-hamKu80                     Ovary; CHO-K1             ECACC
  ***Mus musculus*-- mouse**                                                                                
  142                                            OV3121                           Ovary                     JCRB
  143                                            OV3121-ras4                      Ovary                     JCRB
  144                                            OV3121-ras7                      Ovary                     JCRB
  145                                            p53-def-MOSE                     Ovary                     JCRB
  146                                            T-Ag-MOSE                        Ovary                     JCRB
  ***Sus domesticus*-- Pig**                                                                                
  147                                            AVG-16                           Ovary follicle            ECACC
  ***Spodoptera frugiperda*-- fall army worm**                                                              
  148                                            Sf 9                             Pupal ovary               NCBI/ECACC
  149                                            Sf 9 TitreHigh AC free           Pupal ovary; Sf 9 CL      ECACC
  150                                            Sf 21                            Pupal ovary               NCBI/ECACC
  151                                            Sf 21 TitreHigh AC free          Pupal ovary; Sf 21 CL     ECACC
  ***Esox lucius*-- Northern pike fish**                                                                    
  152                                            PG                               Ovary                     ECACC
  ***Ictalurus punctatus*-- channel catfish**                                                               
  153                                            CCO                              Ovary                     ECACC

It is noteworthy that cell line banks do not stock human cell lines described originating from primary tubal or peritoneal origin. However, only recently the isolation and culturing of normal ovarian and fallopian tube epithelial cells from the same healthy female has been described \[[@B35]\]. This finding may fill the current gap of knowledge and may help clarifying the apparent ambiguity of the origin of 'ovarian cancer' and enabling a clear distinction among ovarian, tubal, and peritoneal cancer at their later stages. However, peritoneal cell lines are still not available as are a subset of histologically distinct ovarian cancer cell lines such as borderline cancers, cystadenomas and carcinosarcomas.

The re-naming of cell lines causes constant confusion as respective annotations are often not found in cell banks. For example, 41 M cells are the same as OAW28 cells. Some cell lines have similar names and require caution in the selection of the cell line of choice: a majority of the animal cell lines and several human cell lines are derived from a parental line (e.g. A2780, CHO) and have been modified *in vitro* to display chemo resistance (e.g. cisplatin-resistant A2780CP) or different cellular factors. In addition, the verification of information given by the cell bank is difficult, because not all cell lines are linked to their original publications and their depositors are rarely mentioned.

One apparent shortcoming is that the ethnicity of the ovarian cancer patient from whom the tumour is derived is indicated in only 30.5%. Apart from the JCRB cell bank where all the deposited cell lines were derived from Japanese females (48.3%), the majority of samples where ethnical details are provided were from Caucasian females.

Since we know that different ethnic groups can have a propensity for specific genetic mutations, for example in the *BRCA* and *APC* genes of Ashkenazi Jews \[[@B36],[@B37]\], it is extremely important to have cell lines that represent the spectrum of ethnic groups around the world. This will reduce the risk of an ethnic bias and ensure that research into different ethnic groups will allow the most benefit for these patients.

The role of genetic changes in the characterization of ovarian cancer cell lines
--------------------------------------------------------------------------------

The (molecular) characterization of EOC in the clinics significantly depends on the presence and type of genetic alterations in the cancer and may define the treatment options and the patients' outcome. The tumor origin where the cell lines derived from was not precisely provided in 51.2% (Table  [4](#T4){ref-type="table"}). Considering the clinico-pathological (histotype, FIGO stage, grade) as essential criteria to categorize EOC in type I and II tumours, the respective information provided by cell banks is not sufficient. The data review on available human ovarian cancer cell lines (n = 95) reflects that cell banks provide the histological subtype in 76.8% with discrepancies to original publications (Table  [5](#T5){ref-type="table"}), stage in 34.7%, and the initial grade in only 20%. In contrast, the information on chemotherapy resistance is provided adequately. Epithelial (-like) cells are characterized with epithelial or stromal markers in more than half (57.9%) of all cell lines, and out of these 85.4% had at least epithelial-like features. Another essential criterion is the doubling time that is provided in only 29.5%.

###### 

Origin of human ovarian cancer cell lines

                                                                       **Origin specified (cell line banks)**           
  -------------------------------------------- ---------------------- ---------------------------------------- ---- --- ---
   **Origin specified (original references)**       **Ascites**                          9                      0    5   0
                 **Metastasis**                          0                               2                      6    0  
               **Not specified**                         0                               0                      11   0  
                   **Ovary**                             0                               0                      9    0  
                                                **Pleural effusion**                     0                      0    0   1

###### 

Histotypes of human ovarian cancer cell lines

                                                                 **Origin specified (cell line banks)**                      
  -------------------------------------------- ---------------- ---------------------------------------- --- --- --- --- --- ---
   **Origin specified (original references)**   **Clear cell**                     6                      0   0   0   0   0   0
                **Endometrioid**                      0                            2                      0   0   0   0   0  
                   **Mixed**                          0                            0                      1   0   0   0   1  
                  **Mucinous**                        0                            0                      0   3   2   0   0  
                   **Other**                          0                            0                      0   0   3   0   0  
                   **Serous**                         0                            0                      0   1   6   7   1  
                                                 **Unknown**                       0                      0   0   0   7   0   1

We also collected and evaluated data provided by cell banks in regards to molecular markers. This information was very limited and only few cell lines were evaluated for expression of progesterone (7.4%) and oestrogen (6.3%) receptors, vimentin (5.3%), *TP53* mutations (4.2%), Her2/neu (3.2%), EpCAM (3.2%), and cytokines 7, 8, 17, 18, and 19 (ranging from 5.3% to 8.4%).

Potential risks of the use of cell lines for in vitro research
--------------------------------------------------------------

The misidentification and cross-contamination of cell lines is problematic in research and may increase the risk for false results and misinterpretations. The extent of misidentification is documented in a recent study wherein a panel of ovarian and endometrial cell lines was analysed by DNA profiling \[[@B38]\]. The authors found that 8 out of the 51 ovarian cancer cell lines were in fact breast cancer, teratocarcinoma, or cervical cancer cell lines and that2 normal endometrial cancer cells were in fact HeLa cervical cancer or MCF-7 breast cancer cells. Likewise, cross-contamination of cell lines, i.e. the accidental generation of mixed cell cultures, is not a lesser problem. Jäger *et al.* 2013 reported that the popular and frequently used KU7 urothelial carcinoma cell line was cross-contaminated years ago with HeLa cells \[[@B39]\]. Cross-contaminations may occur when multiple cell lines are cultured simultaneously (a practice that should be avoided) and becomes only apparent if multiple morphologies are suddenly observed but fatally remains unnoticed if cells have indistinguishable morphology.

Bacterial/fungal/yeast/mycoplasma contamination presents another problem adversely affecting research results. Of these, mycoplasma species are most likely to be detrimental to cell functioning. Unlike most bacterial, fungal or yeast infections, mycoplasma are macroscopically and microscopically undetectable; it may remain in culture for extended periods of time affecting cell growth, gene expression and overall cell functioning \[[@B40]\]. This may be one reason for why different research groups report contradictory findings. For this reason, Cell Bank Australia has collated a database of known cross-contaminated or misidentified cell lines based on the literature. Other cell banks such as the JCRB have also made an effort to screen the database and identified which of their own cell lines were originally misidentified (Table  [1](#T1){ref-type="table"}).

The unavailability of a considerable number of *in vitro* cell line models to the research community is also an issue. The problem is two-fold: firstly, there is no quality control of cells generated in individual laboratories when they are not deposited in a professional cell bank. Even when these cells are meticulously generated and cultured, independent quality checks and verifications are not possible. This flaw is overcome by directly contacting the laboratory where the cell lines were generated. This, however, can lead to the second problem; the passing on of cell lines from laboratory to the other, thereby bypassing the critical quality control cell banks. In the past it has been common practice to obtain cells from collaborating groups, and with the required permission, to again distribute these to other laboratories. Whilst this practice is in the spirit of research collaborations, it increases the risk of receiving contaminated or misidentified cell lines that, in turn, can be detrimental to research.

Conclusions
===========

To ensure a unique quality of cancer research around the world we recommend that all cell lines used for research should be deposited in a cell bank and be readily accessible for all researchers. Ovarian cancer cell bank operators should provide development protocols and comprehensive clinical data for all commercially available cell lines. Depositors of cell lines should ensure that they have carefully collected all relevant clinical information from the donor individuals. This information includes: the exact origin of the cells, the stage during disease progression the cells were taken, the type of therapy the patient underwent prior to sample collection, the data on the patient's survival, the ethnicity and family history (including known genetic alterations), and the preoperative plasma CA125 levels currently provided by only 5.3% of all human ovarian cancer cell lines. Additionally, we recommend that all cell bank operators conform to the same style of reporting the cell line information and only bank cells where all necessary information is available. This will ensure that the highest standard of research is maintained worldwide. Short tandem repeat (STR) profiling, a highly-sensitive method to detect cellular cross-contamination, should be performed by researchers for all newly generated cell lines and should be confirmed by the cell bank once deposited and prior to the sale of the cells. The service for STR profiling is provided by various laboratories, e.g. American Type Cell culture Collection (ATCC-USA, <http://www.atcc.org>), China Center for Type Culture Collection (CCTCC, <http://www.cctcc.org>), Australian Cell Bank ( <http://www.cellbankaustralia.com>), European Culture Collection of Cell Cultures (ECACC, <http://www.hpacultures.org.uk>), or German Cell Culture Collection (DSMZ, <http://www.dsmz.de>). From a recent study that histotyped standard ovarian cancer cell lines by short tandem repeats, immunohistochemistry, and mutation analysis it was concluded that the knowledge of the mutation status of cancer genes such as *ARID1A* and *TP53* and of the general immunoprofile would be beneficial for the determination of the histotype of ovarian cancer cells \[[@B41]\]. Following the model of the Cancer Cell Line Encyclopedia (CCLE), we suggest the establishment of a centralized cell line database that would harbour all the relevant details of new cell lines and would be updated with new details in real time as experimental results are reported in the literature. This is believed to reduce the overlap of research performed and to continually improve the quality and appropriateness of future cell line studies. A cell bank professional with expertise in cancer research would be beneficial for researchers who need advice in correctly choosing the cell line appropriate for a specific research question. The expansion of the current offer of cell lines deposited in the cell banks by additional types of cells is desirable. These include primary, recurrent and metastatic ovarian-, tubal- and peritoneal cancers, a set of cell lines representing all known EOC histotypes, age-matched normal control OSE and tubal cells, and cell lines derived from primary, recurrent and metastatic tumours from the same patients at different progression time points. It is clear that worldwide collaborative efforts are to be taken to reach these recommendations, but we believe that this will be of benefit for the research results in the future.
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